PDCD1 and non-small cell lung carcinoma: To our awareness, this is the first clinical research to identify the prognostic value of MPR for patients with stage IIIA NSCLC after NACT with/without PD-1 inhibitors, and the predictive factors for patients who failed to achieve MPR.